Article
Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service.
Clinical therapeutics - 1 Jul 2020
Armeni Patrizio, Borsoi Ludovica, Fornaro Giulia, Jommi Claudio, Colombo Nicoletta, Costa Francesco
Abstract excerpt
PURPOSE: The aim of this study was to evaluate the cost-effectiveness and net monetary benefit of olaparib maintenance therapy compared with no maintenance therapy after first-line platinum-based chemotherapy in newly diagnosed advanced BRCA1/2-mutated ovarian cancer from the Italian National Health Service (NHS) perspective. METHODS: We developed a lifetime Markov model in which a cohort of patients with newly...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.